Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-06-25
2001-11-13
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800
Reexamination Certificate
active
06316403
ABSTRACT:
Throughout the application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
BACKGROUND OF THE INVENTION
Treatment of ischemic disorders has been the focus of research for many years. The recent availability of transgenic mice has led to a burgeoning number of reports describing the effects of specific gene products on the pathophysiology of stroke. Although focal cerebral ischemia models in rats have been well-described, descriptions of a murine model of middle cerebral artery occlusion are scant, and sources of potential experimental variability remain undefined.
Acute neutrophil recruitment to postischemic cardiac or pulmonary tissue has deleterious effects in the early reperfusion period, but the mechanisms and effects of neutrophil influx in the pathogenesis of evolving stroke remains controversial.
SUMMARY OF THE INVENTION
The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
REFERENCES:
patent: 4711848 (1987-12-01), Insley et al.
patent: 2141641 (1995-08-01), None
Tijburg, et al. (1990) Activation of the Coagulation Mechanism on Tumor Necrosis Factor-stimulated Cultured Endothelial Cells and Their Extracellular Matrix, J. Biol. Chem. 266:12067-12074.
Benedict, C.R., et al., 1994, Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Texas Heat Institute Journal 21:86-90.
Benedict et al. (1991) Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model,J. Clin. Invest.88, 1760-1765.
Brandstetter et al. (PNAS 92:9796-800, 1995).
Bronner et al. (1995) Primary prevention of stroke,New Eng. J. Med.333, 1392-1400.
Brown and Piantadosi (1992) Recovery of energy metabolism in rat after carbon monoxide hypoxia,J. Clin. Invest.89, 666-672.
Carlos and Harlan (1994) Leukocyte-endothelial adhesion molecules,Blood24, 2068-2101.
Connolly et al. (1996) Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion,J. Clin. Invest.97, 209-216.
Connolly et al. (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia,Neurosurgery38, 523-532.
Dawson and Snyder (1994) Gases as biological messengers: nitric oxide and carbon monoxide in the brain,J. Neurosci.14, 5147-5159.
Fassbender et al. (1995) Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke,Stroke26, 1361-1364.
Holdright, D., et al., 1994, Comparison of the effect of heparin and aspiring versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina J. Am. Coll. Cardiol. 24:39-45.
Ishimaru et al. (1991) Effects of successive carbon monoxide exposures on delayed neuronal death in mice under the maintenance of normal body temperature,Biochem. Biophys. Res. Commun.179, 836-840.
Jerome et al. (1994) P-selectin and ICAM-1 dependent adherence reactions: role in the genesis of postichemic no-reflow,Am. J. Physiol.266, H1316-H1321.
Kim et al. (1995) Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks,J. Neurol. Sci.128, 45-50.
Kochaneck and Hallenbeck (1992) Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke,Stroke23, 1367-1379.
Mayevsky et al. (1995) Multiparametric monitoring of the awake brain exposed to carbon monoxide,J. Appl. Physiol.78, 1188-1196.
Okada et al. (1994) P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion,Stroke25, 202-211.
Pinsky et al. (1996) Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies, a mechanism for rapid neutrophil recruitment after cardiac preservation,J. Clin. Invest.97, 493-500.
Schroeter et al. (1994) Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion,J. Neuroimmunol.55, 195-203.
Seekamp et al. (1994) Role of Selectins in local and remote tissue injury following ischemia and reperfusion,Am. J. Pathol.44, 592-598.
Verma et al. (1993) Carbon monoxide: a putative neural messenger,Science259, 381-384; and.
Weyrich et al. (1993) In vivo neutralization of P-selectin protects feline heart endothelium in myocardial ischemia and reperfusion injury,J. Clin. Invest.91, 2620-2629.
Connolly E. Sander
Pinsky David J.
Prestigiacomo Charles J.
Rose Eric A.
Schmidt Ann Marie
Cooper & Dunham LLP
Peselev Elli
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Methods for treating an ischemic disorder and improving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating an ischemic disorder and improving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating an ischemic disorder and improving... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2605854